Amplifying the effect of antigen-specific tolerogenic ImmTOR nanoparticle with engineered Treg selective IL-2

In this presentation, Dr Kei Kishimoto from Selecta BioSciences discusses their ImmTOR technology, which combines a nanoparticle with the approved anti-inflammatory and immunomodulatory drug rapamycin to induce antigen-specific immune tolerance. Dr Kei shares compelling evidence from their Phase I clinical trial that ImmTOR co-administered with the highly immunogenic gout treatment Pegadricase is able to suppress the antibody response to the treatment in a dose-dependent manner. ImmTOR is currently in Phase III clinical trials, with the current trial expected to be completed in Q1 of 2023.

Dr Kishimoto also presents the next generation of the ImmTOR technology, ImmTOR-IL, which combines ImmTOR with an engineered, T-reg selective IL-2 mutein. In mice, a single dose of ImmTOR with IL-2 mutein induces massive expansion of antigen specific T-regulator cells when co-administered with the antigen of interest. Treg-selective IL-2 has considerable potential to work synergistically with the ImmTOR platform in the clinic, with ImmTOR mitigating the immunogenicity of the engineered IL-2 mutein, and the Treg-specific IL-2 enabling dose sparing of ImmTOR.

Dr Kei Kishimoto is the Chief Scientific Officer of Selector Biosciences. Prior to joining Selector, he held leadership positions at Momenta, Millennium and Boehringer Ingelheim. He completed his Doctorate at Harvard and received his Postdoctoral training at Stanford.